Brief: Natco Pharma Says Fresenius Kabi Usa, Llc And Fresenius Kabi Deutschland GmbH Have Filed A Complaint Against Natco Pharma Usa Llc
18/04/2024 05:46
April 18 (Reuters) - Natco Pharma Ltd NATP.NS :
* FRESENIUS KABI USA, LLC AND FRESENIUS KABI DEUTSCHLAND GMBH HAVE FILED A
COMPLAINT AGAINST NATCO PHARMA USA LLC
* COMPLAINT AGAINST CO RELATING TO MARKETING OF DASH PHARMACEUTICALS
DIAZEPAM
INJECTION PREFILLED SYRINGE IN UNITED STATES
* FRESENIUS HAS NOT YET EFFECTUATED SERVICE OF COMPLAINT WHICH IS REQUIRED
TO
COMMENCE LAWSUIT
* NATCO PHARMA INTENDS TO DEFEND MATTER ACCORDINGLY
Further company coverage: NATP.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees